Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global solid tumor testing market size was valued at USD 6.8 billion in 2024. The market is projected to grow from USD 7.4 billion in 2025 to reach USD 12.1 billion by 2031, exhibiting a compound annual growth rate (CAGR) of approximately 8.5% during the forecast period.
Solid tumor testing comprises a suite of medical diagnostic procedures used for the detection, characterization, and monitoring of abnormal mass of tissue, known as solid tumors, which are a hallmark of many cancers. These tests are critical for enabling early diagnosis, guiding personalized treatment strategies such as targeted therapies and immunotherapies, and monitoring treatment response and disease recurrence. The primary methodologies include conventional testing, such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), and non-conventional or next-generation testing, which heavily relies on advanced genomic techniques like Next-Generation Sequencing (NGS) to analyze genetic mutations and biomarkers.
This significant market expansion is driven by the escalating global incidence of cancer, particularly lung, breast, and colorectal cancers, which account for a substantial portion of the demand. Furthermore, advancements in precision medicine and the consequent rise in the adoption of companion diagnostics are creating robust growth opportunities. The market is also characterized by strategic activities from key players. For example, in early 2024, Illumina launched new comprehensive genomic profiling tests designed to expand access to personalized cancer care. Other dominant companies shaping the competitive landscape include F. Hoffmann-La Roche, Thermo Fisher Scientific, Agilent Technologies, and Danaher.
Rising Global Cancer Incidence
The increasing global burden of cancer, particularly solid tumors, is a primary driver for the testing market. The growing and aging population, combined with lifestyle factors, is leading to a higher prevalence of cancers such as lung, breast, colorectal, and prostate. This rise in patient numbers directly fuels the demand for accurate diagnostic and prognostic testing to guide treatment decisions.
Advancements in Precision Medicine
The shift towards personalized or precision oncology is a significant driver. Therapies targeting specific genetic mutations (e.g., EGFR, ALK, BRAF) require companion diagnostics to identify eligible patients. The development and adoption of these targeted therapies create a direct and sustained need for comprehensive solid tumor profiling.
➤ Next-Generation Sequencing (NGS) has revolutionized the scale and efficiency of genomic testing, allowing for the simultaneous analysis of multiple genes from a single tissue sample.
Furthermore, regulatory approvals and clinical guideline recommendations are mandating biomarker testing for certain cancers, making it a standard of care. This institutional push ensures consistent testing volumes and encourages the development of new assays.
MARKET CHALLENGES
Sample Quality and Availability
Obtaining sufficient quantity and high-quality tumor tissue for analysis remains a significant hurdle. Biopsies can be invasive, and samples are often limited, degraded, or contaminated with normal tissue, leading to test failures or inconclusive results. Liquid biopsies are emerging as an alternative but face their own challenges with sensitivity for low tumor fractions.
Other Challenges
Data Interpretation and Standardization
The complexity of genomic data generated by advanced tests like NGS requires sophisticated bioinformatics and expert pathologists for interpretation. A lack of standardized protocols and reporting criteria across laboratories can lead to variability in results, complicating clinical decision-making.
Reimbursement and Cost Constraints
The high cost of comprehensive genomic profiling tests can be a barrier to widespread adoption. Navigating the complex and often slow reimbursement processes from public and private payers can delay patient access to testing and create financial uncertainty for testing laboratories.
Stringent Regulatory Frameworks
The solid tumor testing market is subject to rigorous regulatory oversight from bodies like the FDA in the US and EMA in Europe. The process for obtaining approval or clearance for new tests, especially laboratory-developed tests (LDTs), is time-consuming and expensive. Recent proposals for stricter regulation of LDTs could further slow down innovation and market entry for new assays.
High Capital Investment and Operational Costs
Establishing and maintaining a state-of-the-art molecular diagnostics laboratory requires significant capital investment in advanced instrumentation, such as NGS platforms, and ongoing costs for reagents and skilled personnel. This high barrier to entry can limit the number of new competitors and consolidate the market among a few large players.
Expansion of Liquid Biopsy Applications
Liquid biopsy, which analyzes circulating tumor DNA (ctDNA) from blood samples, presents a massive growth opportunity. Its non-invasive nature allows for repeated testing to monitor treatment response, detect minimal residual disease (MRD), and identify emerging resistance mutations. The technology is expanding from late-stage to earlier-stage cancer management.
Integration of Artificial Intelligence (AI)
The integration of Artificial Intelligence and machine learning into pathology and genomic data analysis offers tremendous potential. AI algorithms can assist in tumor detection, classification, and biomarker identification from complex datasets more quickly and accurately than manual methods, leading to improved diagnostic precision and workflow efficiency.
Emerging Markets and Point-of-Care Testing
There is significant potential for market expansion in emerging economies where cancer incidence is rising, and healthcare infrastructure is improving. Additionally, the development of rapid, decentralized point-of-care testing solutions could democratize access to advanced diagnostics, particularly in remote or resource-limited settings.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Non-Conventional Testing is positioned as the leading category, driven by significant advancements in molecular diagnostics and genomic sequencing technologies. This segment offers superior capabilities for early cancer detection, providing more detailed genetic and molecular profiling of tumors compared to traditional histopathological methods. The shift towards personalized medicine is a primary catalyst, as these advanced tests enable clinicians to identify specific biomarkers and mutations, which are critical for targeted therapy selection. Consequently, the adoption of non-conventional testing is growing rapidly, reflecting a broader industry trend towards precision oncology and more informed, data-driven treatment decisions. |
| By Application |
|
Hospitals represent the dominant application segment due to their role as primary points of care for patients with suspected or diagnosed cancers. The centralization of advanced diagnostic equipment, availability of specialized pathology departments, and the need for integrated patient management from diagnosis through treatment solidifies their leading position. High patient volumes, driven by increasing cancer incidence rates, ensure a consistent demand for tumor testing services within hospital settings. Furthermore, the trend toward establishing comprehensive cancer centers within major hospitals, which combine diagnostics, surgery, and oncology services, reinforces the critical and enduring role of this segment in the market ecosystem. |
| By End User |
|
Oncologists are the foremost end users, as they are the primary physicians responsible for diagnosing cancer, staging the disease, and formulating treatment plans based on test results. Their direct reliance on accurate and comprehensive tumor profiling to make critical therapeutic decisions, such as selecting targeted therapies or immunotherapies, creates substantial and consistent demand. The evolving complexity of cancer treatments necessitates that oncologists utilize sophisticated testing to guide personalized treatment regimens, making them the most influential consumers of solid tumor testing services and driving the development of clinically actionable diagnostic reports. |
| By Technology Platform |
|
Next-Generation Sequencing (NGS) is the leading technology platform, revolutionizing solid tumor testing by enabling high-throughput, multiplexed analysis of genetic alterations from a single tissue sample. Its unparalleled ability to comprehensively profile a wide array of genomic biomarkers, including mutations, fusions, and copy number variations, makes it indispensable for modern oncology. The technology's scalability and decreasing cost are facilitating its integration into routine clinical practice, supporting the expansion of precision medicine. Its dominance is further reinforced by continuous innovations that improve accuracy, speed, and the depth of genomic information available to clinicians. |
| By Tumor Profiling Purpose |
|
Therapeutic Selection emerges as the leading purpose for tumor profiling, highlighting the critical role of testing in guiding treatment decisions. This segment's prominence is driven by the paradigm shift towards targeted therapies and immunotherapies, which require specific biomarker information to identify patients most likely to respond. The value of testing is most directly realized when it informs the choice of a effective treatment regimen, improving patient outcomes and optimizing healthcare resource allocation. This focus on actionable results for therapy selection is a primary driver of market growth and technological advancement, making it the most dynamic and influential segment. |
Strategic Developments and Technological Innovation Define the Market
The global solid tumor testing market is characterized by the presence of a few dominant multinational corporations that hold significant market share through extensive product portfolios, robust global distribution networks, and continuous investment in research and development. F. Hoffmann-La Roche, Illumina, and Thermo Fisher Scientific are widely recognized as leaders. Their competitive strength is anchored in providing integrated solutions that span from advanced genomic sequencing instruments and reagents to comprehensive diagnostic platforms and companion diagnostics, which are critical for personalized cancer treatment strategies. The market structure is consolidated, with these top players engaging in strategic mergers, acquisitions, and partnerships to expand their technological capabilities and geographic footprint. This competitive intensity is driven by the critical need for accurate, early detection of solid tumors to guide effective therapeutic interventions.
Beyond the leading corporations, the market includes several other significant players who compete effectively by focusing on niche technologies or specialized testing services. Companies such as Agilent Technologies and Danaher (through its subsidiary, Beckman Coulter) hold strong positions with their expertise in areas like in situ hybridization and flow cytometry. Furthermore, a growing segment of specialized diagnostic companies and emerging biotech firms are gaining traction by developing innovative non-conventional testing methods, including liquid biopsies and advanced molecular assays. These players often target specific cancer types or offer rapid, high-sensitivity tests that complement the broader offerings of the market leaders, contributing to a dynamic and evolving competitive environment.
List of Key Solid Tumor Testing Companies ProfiledF. Hoffmann-La Roche Ltd.
Agilent Technologies, Inc.
Danaher Corporation (Beckman Coulter)
Qiagen N.V.
Myriad Genetics, Inc.
Guardant Health, Inc.
Foundation Medicine, Inc. (a Roche company)
Exact Sciences Corporation
Bio-Rad Laboratories, Inc.
Siemens Healthineers AG
Abbott Laboratories
HTG Molecular Diagnostics, Inc.
The global market for solid tumor testing is experiencing significant growth, driven by the critical need for early cancer detection. This medical procedure is essential for identifying malignancies before they metastasize, enabling more effective and timely treatment interventions. The market was valued at a substantial figure in 2024 and is projected to reach an even higher value by 2031, with a steady compound annual growth rate. The increasing global incidence of cancer is the primary catalyst behind this expansion, creating sustained demand for diagnostic solutions.
Other TrendsDominance of the Hospital Segment
Hospitals are projected to remain the primary end-user segment in the solid tumor testing market through 2025. This dominance is attributed to several factors, including the high volume of patients with cancer symptoms seeking initial diagnosis and comprehensive care within hospital settings. The availability of advanced diagnostic infrastructure, multidisciplinary oncology teams, and integrated treatment pathways makes hospitals the central hub for tumor testing. The rising prevalence of tumors and other terminal illnesses continues to drive patient flow to hospitals, solidifying their leading position in the market.
Technological Segmentation and Regional DynamicsThe market is segmented into conventional and non-conventional testing methods, with non-conventional techniques, such as advanced genomic sequencing, gaining significant traction due to their high precision. In terms of application, alongside hospitals, diagnostic laboratories and academic research institutes represent key segments contributing to market diversity. Geographically, North America holds a significant market share, supported by advanced healthcare infrastructure and high healthcare expenditure. However, the Asia-Pacific region is anticipated to exhibit rapid growth during the forecast period, driven by increasing healthcare awareness, improving diagnostic capabilities, and a growing patient population.
Regional Analysis: Solid Tumor Testing MarketEurope
Europe represents a major and highly sophisticated market for solid tumor testing, characterized by strong national healthcare systems and a concerted push towards personalized medicine through initiatives like the EU's Mission on Cancer. Countries such as Germany, the UK, and France are leading regional adoption, driven by well-funded public health services and advanced cancer centers. The region navigates a more fragmented regulatory landscape with the evolving IVDR, which aims to harmonize standards but presents initial challenges. Reimbursement pathways vary significantly between countries, influencing the speed of adoption for newer, more expensive tests. Despite this, there is a strong foundation of biomedical research and a high awareness of the clinical utility of biomarker testing, supporting steady market growth. Collaboration across borders for clinical trials and data sharing further propels the advancement of testing capabilities.
Asia-Pacific
The Asia-Pacific region is the fastest-growing market for solid tumor testing, fueled by a massive patient population, increasing cancer incidence, and rapidly improving healthcare infrastructure. Japan and China are the key drivers, with strong government support for genomics and precision medicine. Japan's advanced healthcare system and early adoption of cutting-edge diagnostics contrast with China's vast market potential and significant domestic investment in biotech innovation. The region exhibits diverse market dynamics, with developed countries focusing on technological sophistication while emerging economies prioritize accessibility and cost-effectiveness. Challenges include regulatory heterogeneity and variable reimbursement landscapes, but the overarching trend is toward greater standardization and adoption of genomic testing, making it a critical future growth engine for the global market.
South America
The solid tumor testing market in South America is emerging, with growth primarily concentrated in larger economies like Brazil. Market development is constrained by economic volatility and limitations in healthcare funding, which affect both infrastructure investment and patient access to advanced diagnostics. While major urban cancer centers in countries like Brazil and Argentina offer sophisticated testing capabilities, often in line with international standards, access in rural and less developed areas remains limited. The region shows potential for growth as awareness of precision oncology increases and as governments and private payers begin to recognize the long-term value of targeted therapies. Partnerships with international diagnostic companies are crucial for technology transfer and expanding test availability.
Middle East & Africa
The Middle East and Africa region presents a highly heterogeneous market for solid tumor testing. Wealthier Gulf Cooperation Council countries, such as the United Arab Emirates and Saudi Arabia, are investing heavily in advanced healthcare infrastructure and are early adopters of precision oncology, creating sophisticated hubs for testing. In contrast, much of Africa faces significant challenges, including limited healthcare budgets, inadequate infrastructure, and a high burden of infectious diseases that can overshadow cancer care. Market growth is therefore nascent and uneven, driven by top-tier private hospitals and initiatives in specific countries. International collaborations and efforts to build local diagnostic capacity are key to future market development, focusing initially on essential, cost-effective testing solutions before advancing to more complex genomic profiling.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global solid tumor testing market was valued at USD 6.8 billion in 2024 and is expected to reach USD 12.1 billion by 2031, exhibiting a CAGR of 8.5%.
-> Key players include Illumina, F. Hoffmann-La Roche, Thermo Fisher Scientific, Agilent Technologies, and Danaher, among others.
-> Key growth drivers include rising cancer incidence, advancements in precision medicine, and increasing adoption of companion diagnostics.
-> North America currently leads the market, while Asia-Pacific is showing rapid growth potential.
-> Emerging trends include comprehensive genomic profiling tests and the integration of next-generation sequencing technologies.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates